Berberine

SKU: orb1940991

Description

Berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism. Berberine may as a broad-spectrum anti-microbial medicine, a complementary therapeutic agent for HIV/AIDS. Berberine seems to act as an herbal antidepressant and a neuroprotector against neurodegenerative disorders. Berberine is used in histology for staining heparin in mast cells. As a natural dye, berberine has a colour index of 7516. Berberine reduces hepatic fat content in rats with nonalcoholic fatty liver disease; also prevents proliferation of hepatic stellate cells (HSCs), which are central for the development of fibrosis during liver injury. Berberine can ameliorate proinflammatory cytokines-induced intestinal epithelial tight junction damage in vitro, and berberine may be one of the targeted therapeutic agents that can restore barrier function in intestinal disease states. Berberine has antineoplastic effects, including breast cancer, leukemia, melanoma, epidermoid carcinoma, hepatoma, pancreatic cancer, oral carcinoma, tongue carcinoma, glioblastoma, prostate carcinoma and gastric carcinoma, etc.

Key Properties

• CAS Number: 2086-83-1
• MW: 336.36
• Purity: >98% (HPLC)
• Formula: C₂₀H₁₈NO₄+
• SMILES: COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC
• Target: Estrogen Receptor/ERR

Bioactivity

• In Vivo:
  Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma In vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice. Animal model: 5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts. Dosage: 10, 30, or 50 mg/kg/day. Administration: Gastrointestinal gavage; for 10 consecutive days. Result: Showed inhibitory rates of 33.1 % and 45.3 % at doses of 30 and 50 mg/kg/day.
• In Vitro:
  Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29. Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth. LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase. Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM. Cell Proliferation Assay Cell line: Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29. Concentration: 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM Incubation time: 72 hours. Result: Inhibited the proliferation of four cell lines. The IC50 ranged from 40.8±4.1 μM (LoVo) to 98.6±2.9 μM (HCT116). Cell Proliferation Assay Cell line: Colorectal carcinoma cell lines LoVo. Concentration: 1.25, 2.5, 5, 10, 20, 40, 80, and 160 μM Incubation time: 24, 48, 72 hours. Result: Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 μM induced 71.1±1.9 % growth inhibitions in LoVo cells. Cell Cycle Analysis Cell line: LoVo cells. Concentration: 0, 10, 20, 40, or 80 μM. Incubation time: 24 hours. Result: Exposure to 40.0 μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population. Western blot analysis. Cell line: LoVo cells. Concentration: 10, 20, 40, or 80 μM. Incubation time: 24 hours. Result: Suppressed cyclin B1, cdc2 and cdc25c protein expression.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Estrogen Receptor/ERR